Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 30, 2008 (13 weeks)
Business Overview: Illumina is a leading developer of integrated systems for the large-scale analysis of genetic variation and biological function. The company operates in sequencing, genotyping, and gene expression markets, with a newly created Diagnostics Business Unit showing limited activity in this period. The company operates as a single segment for reporting purposes.
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenue | $121,861 | $72,150 |
| Net Income (Loss) | $13,428 | $(298,076) |
| Diluted EPS | $0.21 | $(5.58) |
| Operating Cash Flow | $(62,755) | $14,643 |
| Cash & Equivalents (End of Period) | $118,614 | $123,529 |
| Total Debt (Current Portion) | $400,006 | $16 |
| Product Gross Margin | 61.6% | 64.4% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 69% to $121.9 million, driven by an 81% increase in product revenue. Growth was fueled by increased instrument shipments (Genome Analyzer and GAII) and strong demand for Infinium consumable products.
- Profitability Turnaround: The company reported a net income of $13.4 million, a significant improvement from a net loss of $298.1 million in the prior year. The prior year loss was heavily impacted by a $303.4 million non-cash charge for acquired in-process research and development (IPR&D) from the Solexa acquisition.
- Debt Reclassification: The $400 million Convertible Senior Notes were reclassified from long-term to current liabilities because the notes became convertible into cash and shares during the quarter (March 31 to June 29, 2008).
- Operating Cash Flow: Operating cash flow turned negative ($62.8 million outflow) primarily due to a $90.0 million one-time cash payment to settle litigation with Affymetrix and changes in working capital.
- Investment Impairment: The company recorded a $2.4 million unrealized loss on auction rate securities due to market illiquidity, though management deems the impairment temporary.
Guidance, Outlook, and Risks
- Convertible Notes Liquidity Risk: Management disclosed that while the $400 million convertible notes are currently convertible, the company does not have sufficient cash to pay the full principal amount if all notes were converted immediately. However, based on trading prices, conversion is not currently expected. Failure to pay upon conversion would result in a default.
- Product Launches: The company launched the Genome Analyzer II (GAII) and the iScan System. New Infinium HD products (Human1M-Duo and Human610-Quad) were introduced to increase throughput and reduce DNA input requirements.
- Legal Proceedings: The company settled its litigation with Affymetrix for $90.0 million ($36 million capitalized as intangible assets, $54 million expensed). Ongoing litigation with Applied Biosystems regarding patent ownership continues, though no infringement claims are currently asserted against Illumina.
- Market Risks: Risks include intense competition, potential obsolescence of technology, manufacturing capacity constraints, and the impact of global credit market conditions on the liquidity of the investment portfolio.
Investor Verification Checklist
- Convertible Note Conversion: Verify the current trading price of the stock relative to the conversion price ($43.66) to assess the likelihood of conversion and the associated cash outflow risk.
- Auction Rate Securities: Monitor the liquidity status of the $53.5 million in auction rate securities and any further unrealized losses or reclassifications.
- Product Mix Impact: Track the ratio of instrument sales to consumable sales, as a shift toward lower-margin instruments may pressure gross margins.
- Capital Expenditures: Review progress on the planned $25.0 million capital expenditure budget for 2008 to support manufacturing expansion.
- Legal Settlements: Confirm no new material litigation arises following the Affymetrix settlement and monitor the status of the Applied Biosystems patent dispute.